- Home
- GCTS vs ACIU Comparison
GCTS vs ACIU Comparison
Compare GCTS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCTS | ACIU |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.9M | 247.6M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GCTS | ACIU |
|---|---|---|
| Price | $2.12 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.54 |
| AVG Volume (30 Days) | ★ 1.2M | 166.5K |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,866,000.00 | N/A |
| Revenue This Year | $772.99 | $422.39 |
| Revenue Next Year | $152.91 | $377.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.96 | $2.10 |
| 52 Week High | $3.93 | $4.00 |
Technical Indicators
Market Signals| Indicator | GCTS | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 42.98 |
| Support Level | $1.70 | $2.13 |
| Resistance Level | $2.27 | $2.68 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 57.86 | 20.92 |
Price Performance
Historical ComparisonAbout GCTS GCT Semiconductor Holding Inc.
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.